ENTA
ENANTA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$10.65
+2.70%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$10.49
From 52W high−36.80%
Volume251487.00
Market cap$310.19M
P/E (TTM)—
P/S (TTM)4.8x
Div yield—
Key dataNov 4, 2026
Open
$10.49
From 52W high
−36.80%
Volume
251487.00
Market cap
$310.19M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
34.4
MomentumView details →
1D Return
+2.70%
YTD Return
−34.09%
SummaryUpdated Jun 1, 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a biotechnology company founded in 1995 and headquartered in Watertown, Massachusetts. The company specializes in discovering and developing small molecule drugs for treating viral infections and liver diseases. Enanta went public in March 2013 and has established itself as a focused developer of antiviral therapeutics, with a particular emphasis on respiratory viruses and hepatitis treatments. The company operates primarily as a research and development organization, with revenue generated through royalty agreements from previously developed drugs and ongoing clinical development programs.
Similar companies
Latest newsMore news →
ENANTA PHARMACEUTICALS INC appointed Tara L. Kieffer as chief operating officer, effective October 28, 2026.7d agoEnanta Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 trial of zelicapavir in adults at high risk of severe outcomes from RSV infection.10d ago